glp-1 treatment phoenix Weight Loss for Arizona | Affinity Whole Health GLP-1 Weight Loss Program |

Contouring treatment for most body types, its effectiveness can depend on several factors

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

How do I book an appointment

Of note, more holistic metrics that provide insights into the overall healthiness and nutritional quality of the purchased food have been developed